Innovation medicine has a fundamental value for patients, physicians, the healthcare system and society as a whole. In the last few decades alone, the discovery and development of new innovative therapies have contributed to increasing the quality and life expectancy of people around the world, saving costs for healthcare systems, and even improving social progress by creating healthier and more productive societies.
In Argentina, the contribution of the sector is profound and relevant, having an impact not only on the health of the population, but also, and decisively, on the economy and development of our country. Today, the pharmaceutical innovation industry is a leader in investment in Research and Development, exceeding 41 billion current pesos in 2021, a growth of more than 130% since 2017.
According to the last Survey on R&D of the Argentine Business Sector published by the Ministry of Science, Technology and Innovation, the contribution in clinical research represents more than 40% of all investment in Research and Development in the country. This means that only 62 companies, out of a total of between 1,500 and 2,000 surveyed in the report, generate almost half of the global investment in the productive sector. And in this sense, not only is Johnson & Johnson one of the companies that invests the most in R&D globally, but Janssen in Argentina belongs to the top 10 companies with the highest investment within the industry.
Additionally, clinical research generates qualified and quality employment and every day we are more who are part of this industry. The sector stands out not only for the increase in demand for specialized professionals, which today concentrates more than 20% of the human resources dedicated to Research and Development in Argentina, but also for the high level of female participation which doubles the average for the business sector as a whole.
And no less remarkable, the promotion of clinical research collaborates with the development of knowledge, skills and abilities in the healthcare industry. Through ongoing local research and development efforts, patients have early access to transformational therapies, and healthcare professionals can embrace cutting-edge practices and technologies alongside their peers around the world.
Without going any further, 3 years ago when the pandemic was looming, we saw how Argentina had early access to vaccines against COVID-19 thanks to innovation laboratories that brought clinical studies to the country. The same is the case with therapies for rare diseases, cancer drugs or the latest innovations in gene therapy.
The value of pharmaceutical innovation is clear and its potential for Argentine economic and productive development is promising. We are sure that our country has the professional quality and scientific capacity to become a benchmark in clinical research for our region. For this reason, we must continue promoting policies that protect and promote it.
On Clinical Research Day, a date that today commemorates 276 years of the first randomized clinical study, those of us who are part of the innovative pharmaceutical industry reaffirm our purpose: to promote access to innovative therapies to improve the lives of patients. Our commitment is strong and long term and we will continue working for more clinical research in the country in order to generate more innovation, more employment and, above all, more health for all.
Director of Clinical Studies at Janssen Argentina
Source: Ambito
David William is a talented author who has made a name for himself in the world of writing. He is a professional author who writes on a wide range of topics, from general interest to opinion news. David is currently working as a writer at 24 hours worlds where he brings his unique perspective and in-depth research to his articles, making them both informative and engaging.
